Syndax Pharmaceuticals, Inc.
SNDXNASDAQHealthcare● Active
$16.96
$-0.38(-2.19%)
Market Cap$1.5B
P/E Ratio—
52W High$25.59
52W Low$8.585
Syndax Pharmaceuticals, Inc. (SNDX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SNDX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 30, 2026EPS Actual
-$0.48
Est. -$0.59 · +18.6%
Revenue
$0.06B
Est. $0.07B · -7.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 30, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 1-Quarter EPS Beat Streak
SNDX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 3, 2026 | -$0.45 | — | — | — | $0.08B | — |
| ▲ Q2 FY2026 | Apr 30, 2026 | -$0.59 | -$0.48 | +18.6% | $0.06B | $0.07B | -7.0% |
| ▼ Q1 FY2026 | Feb 26, 2026 | -$0.58 | -$0.78 | -33.5% | $0.07B | $0.06B | +6.9% |
| ▲ Q4 FY2025 | Nov 3, 2025 | -$0.74 | -$0.70 | +5.4% | $0.05B | $0.06B | -27.6% |
| ▲ Q3 FY2025 | Aug 4, 2025 | -$1.00 | -$0.83 | +17.0% | $0.04B | $0.05B | -16.9% |
| ▲ Q2 FY2025 | May 5, 2025 | -$1.04 | -$0.98 | +5.8% | $0.02B | $0.02B | +8.1% |
| ▼ Q1 FY2025 | Mar 3, 2025 | -$1.08 | -$1.10 | -1.9% | $0.01B | $0.01B | -39.9% |
| ▲ Q4 FY2024 | Nov 5, 2024 | -$1.13 | -$0.98 | +13.3% | $0.01B | $0.12B | -89.2% |
Q3 FY2026
Aug 3, 2026
EPS Actual
—
EPS Est.
-$0.45
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 30, 2026Beat
EPS Actual
-$0.48
EPS Est.
-$0.59
EPS Surpr.
+18.6%
Revenue
$0.06B
Q1 FY2026
Feb 26, 2026Miss
EPS Actual
-$0.78
EPS Est.
-$0.58
EPS Surpr.
-33.5%
Revenue
$0.07B
Q4 FY2025
Nov 3, 2025Beat
EPS Actual
-$0.70
EPS Est.
-$0.74
EPS Surpr.
+5.4%
Revenue
$0.05B
Q3 FY2025
Aug 4, 2025Beat
EPS Actual
-$0.83
EPS Est.
-$1.00
EPS Surpr.
+17.0%
Revenue
$0.04B
Q2 FY2025
May 5, 2025Beat
EPS Actual
-$0.98
EPS Est.
-$1.04
EPS Surpr.
+5.8%
Revenue
$0.02B
Q1 FY2025
Mar 3, 2025Miss
EPS Actual
-$1.10
EPS Est.
-$1.08
EPS Surpr.
-1.9%
Revenue
$0.01B
Q4 FY2024
Nov 5, 2024Beat
EPS Actual
-$0.98
EPS Est.
-$1.13
EPS Surpr.
+13.3%
Revenue
$0.01B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.18 | $-0.16 | $-0.14 | 6 |
| Q3 FY2027 | $-0.11 | $-0.10 | $-0.09 | 3 |
| Q2 FY2027 | $-0.26 | $-0.24 | $-0.20 | 5 |
| Q1 FY2027 | $-0.10 | $-0.09 | $-0.08 | 3 |
| Q4 FY2026 | $-0.44 | $-0.39 | $-0.33 | 6 |
| Q3 FY2026 | $-0.65 | $-0.42 | $-0.23 | 8 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 7 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 4 |
| Q2 FY2027 | $0.1B | $0.1B | $0.1B | 6 |
| Q1 FY2027 | $0.1B | $0.1B | $0.1B | 4 |
| Q4 FY2026 | $0.1B | $0.1B | $0.1B | 7 |
| Q3 FY2026 | $0.1B | $0.1B | $0.1B | 8 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 30, 2026 | +18.6% | $20.63 | $21.43 | +3.88% |
| ▼ Q1 FY2026 | Feb 26, 2026 | -33.5% | $20.75 | $20.67 | -0.39% |
| ▲ Q4 FY2025 | Nov 3, 2025 | +5.4% | $13.70 | $13.76 | +0.44% |
| ▲ Q3 FY2025 | Aug 4, 2025 | +17.0% | $9.98 | $10.38 | +4.01% |
| ▲ Q2 FY2025 | May 5, 2025 | +5.8% | $13.73 | $13.57 | -1.17% |
| ▼ Q1 FY2025 | Mar 3, 2025 | -1.9% | $15.64 | $15.48 | -1.02% |
| ▲ Q4 FY2024 | Nov 5, 2024 | +13.3% | $18.94 | $19.69 | +3.96% |
| ▲ Q3 FY2024 | Aug 1, 2024 | +12.1% | $22.70 | $22.00 | -3.08% |
Q2 FY2026+3.88%
Report Date
Apr 30, 2026
EPS Beat/Miss
+18.6%
Price Before
$20.63
Price After
$21.43
Q1 FY2026-0.39%
Report Date
Feb 26, 2026
EPS Beat/Miss
-33.5%
Price Before
$20.75
Price After
$20.67
Q4 FY2025+0.44%
Report Date
Nov 3, 2025
EPS Beat/Miss
+5.4%
Price Before
$13.70
Price After
$13.76
Q3 FY2025+4.01%
Report Date
Aug 4, 2025
EPS Beat/Miss
+17.0%
Price Before
$9.98
Price After
$10.38
Q2 FY2025-1.17%
Report Date
May 5, 2025
EPS Beat/Miss
+5.8%
Price Before
$13.73
Price After
$13.57
Q1 FY2025-1.02%
Report Date
Mar 3, 2025
EPS Beat/Miss
-1.9%
Price Before
$15.64
Price After
$15.48
Q4 FY2024+3.96%
Report Date
Nov 5, 2024
EPS Beat/Miss
+13.3%
Price Before
$18.94
Price After
$19.69
Q3 FY2024-3.08%
Report Date
Aug 1, 2024
EPS Beat/Miss
+12.1%
Price Before
$22.70
Price After
$22.00
Avg Beat Reaction+1.34%
Avg Miss Reaction-0.71%
Beat Rate6 / 8 quarters
Largest Move+4.01% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SNDX ends December
Syndax Pharmaceuticals, Inc. (SNDX) most recently reported earnings on April 30, 2026 for Q2 FY2026, posting EPS of $-0.48 — beating the analyst consensus of $-0.59 by +18.6%. The next SNDX earnings date is expected around September 1, 2026.
Each quarter, investors track SNDX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SNDX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SNDX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SNDX earnings · 5 questionsSyndax Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. SNDX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SNDX historically reports after market close (AMC).
SNDX earnings datewhen is SNDX earningsSNDX next earnings datewhen does SNDX report earningsSNDX earnings calendar
▸ Source: FMP · Syndax Pharmaceuticals, Inc. SEC filings · US GAAP · Syndax Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026